BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 35283317)

  • 1. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies.
    Mustafayev K; Torres H
    Clin Microbiol Infect; 2022 Oct; 28(10):1321-1327. PubMed ID: 35283317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors.
    Chiu CY; Ahmed S; Thomas SK; Wang LS; Mustafayev K; Fayad LE; Wierda WG; Khawaja F; Torres HA
    Clin Lymphoma Myeloma Leuk; 2023 Aug; 23(8):610-615. PubMed ID: 37150651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral therapy use and related outcomes in patients with cancer and viral infections: results from SWOG S1204.
    Hwang JP; Arnold KB; Unger JM; Chugh R; Tincopa MA; Loomba R; Hershman D; Ramsey SD
    Support Care Cancer; 2022 Dec; 31(1):93. PubMed ID: 36585488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection.
    Megna M; Patruno C; Bongiorno MR; Gambardella A; Guarneri C; Romita P; Raimondo A; Loconsole F; Fabbrocini G
    Clin Drug Investig; 2022 Jun; 42(6):525-531. PubMed ID: 35633470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Hepatitis B Virus and Hepatitis C Virus Infections in Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Mustafayev K; Mallet V; Torres HA
    J Immunother Precis Oncol; 2024 May; 7(2):111-121. PubMed ID: 38721408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations.
    Piaserico S; Messina F; Russo FP
    Am J Clin Dermatol; 2019 Dec; 20(6):829-845. PubMed ID: 31222626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
    Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
    World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update.
    Hwang JP; Feld JJ; Hammond SP; Wang SH; Alston-Johnson DE; Cryer DR; Hershman DL; Loehrer AP; Sabichi AL; Symington BE; Terrault N; Wong ML; Somerfield MR; Artz AS
    J Clin Oncol; 2020 Nov; 38(31):3698-3715. PubMed ID: 32716741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.
    De Monte A; Courjon J; Anty R; Cua E; Naqvi A; Mondain V; Cottalorda J; Ollier L; Giordanengo V
    J Clin Virol; 2016 May; 78():27-30. PubMed ID: 26967675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System.
    Bersoff-Matcha SJ; Cao K; Jason M; Ajao A; Jones SC; Meyer T; Brinker A
    Ann Intern Med; 2017 Jun; 166(11):792-798. PubMed ID: 28437794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus (HBV) reactivation-The potential role of direct-acting agents for hepatitis C virus (HCV).
    Blackard JT; Sherman KE
    Rev Med Virol; 2018 Jul; 28(4):e1984. PubMed ID: 29761585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.
    Mücke MM; Backus LI; Mücke VT; Coppola N; Preda CM; Yeh ML; Tang LSY; Belperio PS; Wilson EM; Yu ML; Zeuzem S; Herrmann E; Vermehren J
    Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):172-180. PubMed ID: 29371017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review.
    Pu D; Yin L; Zhou Y; Li W; Huang L; Cai L; Zhou Q
    Medicine (Baltimore); 2020 Jan; 99(5):e19013. PubMed ID: 32000444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of psoriasis patients with hepatitis B or hepatitis C virus infection.
    Bonifati C; Lora V; Graceffa D; Nosotti L
    World J Gastroenterol; 2016 Jul; 22(28):6444-55. PubMed ID: 27605880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy.
    Kawagishi N; Suda G; Sakamori R; Matsui T; Onozawa M; Yang Z; Yoshida S; Ohara M; Kimura M; Kubo A; Maehara O; Fu Q; Hosoda S; Tokuchi Y; Suzuki K; Nakai M; Sho T; Morikawa K; Natsuizaka M; Ogawa K; Sakai H; Ohnishi S; Baba M; Takehara T; Sakamoto N
    Sci Rep; 2022 Oct; 12(1):16800. PubMed ID: 36207368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mechanism and clinical significance of HBV reactivation after anti-HCV therapy].
    Zeng WJ; Gao L; Xu YW; Chen XM; Wang FS; Lu FM
    Zhonghua Gan Zang Bing Za Zhi; 2022 Sep; 30(9):997-1001. PubMed ID: 36299197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV).
    Pisaturo M; Macera M; Alessio L; Calò F; Coppola N
    Viruses; 2019 Sep; 11(9):. PubMed ID: 31540223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents.
    Huang SC; Cheng PN; Liu CH; Yang HC; Su TH; Tseng TC; Chen PJ; Kao JH; Liu CJ
    J Formos Med Assoc; 2022 May; 121(5):920-929. PubMed ID: 34538552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.
    Kawagishi N; Suda G; Onozawa M; Kimura M; Maehara O; Ohara M; Izumi T; Umemura M; Ito J; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N
    J Viral Hepat; 2017 Dec; 24(12):1098-1106. PubMed ID: 28632923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C.
    Aggeletopoulou I; Konstantakis C; Manolakopoulos S; Triantos C
    World J Gastroenterol; 2017 Jun; 23(24):4317-4323. PubMed ID: 28706414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.